Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
100 hedge funds and large institutions have $121M invested in Paratek Pharmaceuticals, Inc. in 2020 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 33 increasing their positions, 29 reducing their positions, and 15 closing their positions.
454% more call options, than puts
Call options by funds: $2.21M | Put options by funds: $399K
14% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 29
13% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 15
9% more capital invested
Capital invested by funds: $111M → $121M (+$10.2M)
1% more funds holding
Funds holding: 99 → 100 (+1)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Bruce & Co
Chicago,
Illinois
|
+$1.55M |
| 2 |
BlackRock
New York
|
+$1.33M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.26M |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$854K |
| 5 |
GAI
General American Investors
New York
|
+$718K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$2M |
| 2 |
Morgan Stanley
New York
|
-$685K |
| 3 |
BBVA
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
|
-$548K |
| 4 |
Squarepoint
New York
|
-$471K |
| 5 |
WIC
Water Island Capital
New York
|
-$449K |
PRTK Hedge Fund Activity: Q3 2020 in Review
100 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q3 2020, worth a combined $121M — up 9.2% from $111M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new PRTK positions and 15 closed out — a net gain of 2 holders — while 33 added to existing stakes and 29 trimmed.
The largest buyer was Bruce & Co, adding an estimated $1.55M. The largest seller was D.E. Shaw & Co, cutting an estimated $2M.
- 100 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q3 2020, up from 99 in Q2 2020.
- Funds reported $121M of Paratek Pharmaceuticals, Inc. stock for Q3 2020, up 9.2% quarter-over-quarter.
- 17 funds opened new Paratek Pharmaceuticals, Inc. positions in Q3 2020 and 15 closed out, a net change of +2 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q3 2020 was Bruce & Co, an estimated $1.55M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q3 2020 was D.E. Shaw & Co, an estimated $2M sold.
Based on aggregated 13F filings for Q3 2020.